Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance.
about
PI3K/Akt/mTOR inhibitors in breast cancerPotential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor-positive advanced breast cancerRecent advances in the development of anti-HER2 antibodies and antibody-drug conjugatesRhodacyanine derivative selectively targets cancer cells and overcomes tamoxifen resistance3, 3'-Diindolylmethane enhances the effectiveness of herceptin against HER-2/neu-expressing breast cancer cellsStrategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials.Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer.Inhibition of Integrin-HER2 signaling by Cucurbitacin B leads to in vitro and in vivo breast tumor growth suppressionThe PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers.Identification of collaborative driver pathways in breast cancer.EgoNet: identification of human disease ego-network modulesHER2 mediated de novo production of TGFβ leads to SNAIL driven epithelial-to-mesenchymal transition and metastasis of breast cancerResistance to HER2-targeted therapies: a potential role for FOXM1.Deciphering the role of insulin-like growth factor-I receptor in trastuzumab resistance.Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapyMolecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast CancerTrastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancerTargeting of antigens to B lymphocytes via CD19 as a means for tumor vaccine development.New developments in the treatment of HER2-positive breast cancerComputational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds.Cellular glycosylation affects Herceptin binding and sensitivity of breast cancer cells to doxorubicin and growth factors.ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapyEverolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer.A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer.Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer.A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.Exploring the dynamics and interaction of a full ErbB2 receptor and Trastuzumab-Fab antibody in a lipid bilayer model using Martini coarse-grained force field.20(S)-Protopanaxadiol-Induced Apoptosis in MCF-7 Breast Cancer Cell Line through the Inhibition of PI3K/AKT/mTOR Signaling Pathway.Synergistic antitumor activity by combining trastuzumab with retinoic acid in HER2 positive human breast cancer cells.Role for the transcriptional activator ZRF1 in early metastatic events in breast cancer progression and endocrine resistance.
P2860
Q26771394-8FA93C38-D4EA-44DD-BF90-215C7EB41A0FQ26775361-6B7E50AF-AF6F-4D0E-9CD9-AAF9FB0B5C3FQ28083123-5F6A8279-1B4A-487D-9A05-74073C713893Q28482597-FF1B4ABF-A9C3-420B-A887-A8262CD9E650Q28485231-752A374E-644C-4669-B5BD-7230EB20BFCEQ30857631-FFA59F61-7483-4471-8311-72BAC5073F2BQ33674656-DC7E29B9-60DE-493B-8266-A9AFF4F7CA30Q33688434-5842F22E-3AAE-4AB0-AF23-505651901759Q33937368-1478808B-626C-47A9-AA6D-C933DD163678Q33953601-AB694762-7331-49C6-BB09-30AEB3BB34E9Q34525552-BE05D9E5-45EA-40E5-A58E-318F5D24B992Q34614133-77F097FF-63BA-4167-B059-6891437ACCCBQ34955355-4D4082BA-F034-4AEE-84E1-0C37A21F0A37Q36102124-108DBD4A-6254-4B0E-8B6F-1E9D3D976502Q36116250-B5433B4F-0ADE-4A7C-9F84-E0254D456CA4Q36440214-8E3A8994-DC88-4913-836D-695F553F89F3Q36585636-43E0663F-EFAB-4D41-AF70-B1ABFC1CDDD7Q36864003-79C68867-E13D-4285-AE3B-904F674621ABQ37016382-A3E9CE69-C6F0-4434-967B-80DC3D065F86Q37644761-2C0D5627-196B-4979-8428-C4C544B43C9CQ37657607-937EBFA7-E766-42AD-851D-5D72F57E0A72Q37662351-A4DF37FD-04E4-45D6-BFE3-3CE5CF0C9EB1Q39520887-1F0F006A-5CAF-4693-9AF5-6538A9F0C5EEQ41173029-F984AD74-46C1-4186-A2CB-97CB26BE6678Q42541148-9D82DB53-CF13-4CB4-A7BE-1BB56613CFABQ47094892-953B3508-59C4-415F-96C3-FA791B53CCFEQ48134448-410D0CA6-7460-4B19-82A4-542A323D3796Q52652923-8D5AAB1F-E63A-4461-9BAF-BD8FA7368953Q52721972-110372C0-CF49-44D6-A74D-BC2F4A11D28CQ55317203-8FAAC187-E58F-4CBA-BE26-872D5D6F1CDFQ55480165-1D1E41D6-D466-4EB5-9FA8-924A3E6EA0A9
P2860
Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance.
@ast
Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance.
@en
type
label
Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance.
@ast
Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance.
@en
prefLabel
Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance.
@ast
Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance.
@en
P2860
P1476
Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance.
@en
P2093
P2860
P304
P356
10.2174/092986712799320691
P577
2012-01-01T00:00:00Z